Martin D Goodman, MD is an Assistant Professor of Surgery and Director of the Advanced Abdominal Tumor and Peritoneal Surface Malignancy Program at Tufts Medical Center.

After completing a surgical oncology fellowship at the University of Pittsburgh, Dr. Goodman took a position as the Director of Surgical Oncology at the Dorothy Schneider Cancer Center in California. He developed a Peritoneal Surface Malignancy Program which was the only center in Northern California.

Dr. Goodman was actively recruited to join the staff at Tufts Medical Center and became the Director of the Advanced Abdominal Tumor and Peritoneal Surface Malignancy Program July 2007. Currently the program is very active dealing with patients with cancers of the Appendix, (pseudomyxoma peritonei) Colon, Ovary, Stomach and Peritoneal Mesothelioma.

Dr. Goodman’s interests include all aspects of surgical oncology including minimally invasive surgery and metastatic disease. He performs surgical techniques for tumors of the liver, pancreas, stomach, colon, and abdominal cavity.

Dr. Goodman has a research interest in treating advanced carcinomas of the peritoneal cavity.

He is a member of the Society of Surgical Oncology, a Fellow of the American College of Surgeons, the American Society of Clinical Oncologists, and the Society for Surgery of the Alimentary Tract.

This book investigates in a variety of complex and interesting ways. The volume details major clinical trails to date. Authors also examine regional approaches to therapy, systemic therapy, and the use of carboplatin and paclitaxel as the standard treatment for women with stages III and IV ovarian cancer. The future direction of intraperitoneal chemotherapy both normothermic and hyperthermic is also covered.

Dr Helm graduated in medicine from Cambridge University, Cambridge, UK and the Middlesex Hospital, London, UK and after training in surgery and obstetrics and gynecology he has focused his professional career on the specialty of gynecologic cancer.

His main interest is the use of intraperitoneal chemotherapy, including hyperthermic intraperitoneal chemotherapy (HIPEC) treatment for gynecologic cancers involving the peritoneal cavity including ovarian cancer and endometrial cancer. He is the Principal Investigator on two international studies of HIPEC for ovarian cancer based at Saint Louis University.

Dr. Helm has an active interest in student and post-graduate training. He has received awards for his student teaching and he participates as invited faculty on open surgery and laparoscopic surgery courses for physicians. He initiated and directs a course to teach gynecologic oncologists the skills necessary for extensive resection of gynecologic cancers involving the upper abdomen and bowel. This course has taught attendees from many different countries around the world. Dr Helm has published widely about HIPEC for ovarian and endometrial cancer both in peer-reviewed journals and in medical textbooks and has been an invited lecturer in many countries.

This issue of the “Surgical Oncology Clinics of North America, Guest” Edited by Dr. Jesus Esquivel, will focus on the current status and future directions of the treatment of the most common peritoneal surface malignancies: appendix cancer, colorectal cancer, ovarian cancer, gastric cancer, and peritoneal mesothelioma. This issue will also outline some of the most common issues that arise regarding cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), such as pharmacokinetic rationale of heat and intraperitoneal chemotherapy, HIPEC techniques and safety considerations, how to start a peritoneal surface malignancy program, anesthesia considerations during cytoreductive surgery and HIPEC, patient selection for cytoreductive surgery and HIPEC, and the role of systemic chemotherapy in the management of peritoneal surface malignancies of appendiceal and colorectal origin.

After completing his General Surgery training program, Dr Esquivel did a two year fellowship in Gastrointestinal Surgical Oncology and Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy with Dr Paul H Sugarbaker at the Washington Cancer Institute.

After completing this fellowship in 1999, Dr Esquivel stayed at the Washington Cancer Institute until December of 2004 when he moved to St Agnes Hospital in Baltimore, Md to become the Director of the Peritoneal Surface Malignancy Program.

Dr Esquivel’s practice is focused exclusively in Peritoneal Surface Malignancies of Appendix, Colon, Ovary, Stomach and Peritoneal Mesothelioma.